Navigation Links
Cipher reports third quarter fiscal 2007 results
Date:11/7/2007

uled with the FDA in November 2007 to further discuss the issues raised in the action letter. The Company will determine the most appropriate path forward to achieve final regulatory approval based in part on the outcome of these discussions with the FDA. Cipher continues to believe its submission includes sufficient efficacy data to support regulatory approval.

Notice of Conference Call

-------------------------

Cipher will hold a conference call today, November 7, 2007, at 8:30 a.m. (ET) to discuss its financial results and other corporate developments. To access the conference call by telephone, dial 416-644-3424 or 1-800-732-1073. A live audio webcast of the call will be available at http://www.cipherpharma.com. The webcast will be archived for 90 days.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals is a drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher's products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company's lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by ProEthic Pharmaceuticals under the label Lipofen(TM). In addition, Cipher is developing formulations of the pain reliever tramadol and the acne treatment isotretinoin.

Cipher is listed on the Toronto Stock Exchange under the symbol 'DN
'/>"/>

SOURCE Cipher Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... November 23, 2014 Asher Milgrom, ... Aesthetics & Wellness was recently featured on ... is president and CEO of American Medical Aesthetics & ... Milgrom received a full scholarship to attend an M.D./Ph.D ... School at the University of Chicago, where his field ...
(Date:11/23/2014)... BambooFlooringChina.com , the world’s leader in bamboo flooring, ... flooring collection. Now, the business is announcing big discounts ... promotion is valid until Dec. 20, 2014. , The new ... dust-free surface, which makes it very easy to maintain. As ... wants to make its website the best shopping platform for ...
(Date:11/22/2014)... PrettyTailor , an outstanding dress ... big promotion. Customers can buy new dresses at its ... visit its website. , As a matter of fact, ... It mainly provides four types of wedding outfits, including ... girl dresses. It also provides a variety of occasion ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 Today, Dylan ... its new collection of wedding dresses; the business offers ... other related accessories for ladies worldwide, allowing them to ... manager of the company, this new collection of chic ... launch. Moreover, they are offered at discounted rates now. ...
(Date:11/22/2014)... 22, 2014 Nocturia is defined ... complaint that the individual has to wake at ... report “Nocturia – Pipeline Review, H2 2014” provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ...
Breaking Medicine News(10 mins):Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4
... PA, 23 February 2011 - Understanding the genetics of ... specific genetic variations associated with this disorder has been ... Psychiatry implicates a brain protein called Piccolo in ... of neuronal proteins, Piccolo is a member of a ...
... increasingly popular in maternity care, but healthcare professionals need ... to a review in the March issue of the ... There is also need for greater respect and cooperation ... patients about the growing use of CAM. ...
... 2011 New research shows that medications which have ... may not have gotten approval from the Food and ... retention had been better understood. Fluid retention may explain ... medications such as Vioxx, Bextra, and Avandia. The research ...
... Feb. 23 (HealthDay News) -- People,s emotional response to challenges ... a new study. To reach that conclusion, researchers from ... a laboratory in front of a video camera and a ... the speech, and they were later asked about the emotions ...
... electronic health record system in Canada, e-health policy must ... health care reform and must take a bottom-up approach ... study published in CMAJ ( Canadian Medical ... Canada Health Infoway has invested almost $1.6 billion ...
... available in French . An electronic health ... Canada and more must be done to speed up the implementation ... be put in place effectively, doctors and front line health care ... role. These are the findings of an innovative new study assessing ...
Cached Medicine News:Health News:A new clue to the genetics of bipolar disorder: Piccolo 2Health News:Review highlights need for more education and guidance on CAM use in midwifery 2Health News:Review highlights need for more education and guidance on CAM use in midwifery 3Health News:New hypothesis explains why drugs increase risk of heart attacks and strokes 2Health News:New hypothesis explains why drugs increase risk of heart attacks and strokes 3Health News:New hypothesis explains why drugs increase risk of heart attacks and strokes 4Health News:E-health must align with health care reform 2Health News:E-health must be a priority, researchers say 2
(Date:11/21/2014)... -- Michael DeMarco (42) erinnert sich kaum ... 2014 zugetragen hat. Seine Tochter Aly Demarco (13) wird ... - http://youtu.be/5cVoMCe0uiE „Man hat ... zu machen", erzählt Michael DeMarco . „Meine Frau ... Anhänger der CrossFit-Trainingsmethode. Ich war auf dem Fahrrad, stand ...
(Date:11/21/2014)... CORAL GABLES, Fla. , Nov. 20, 2014 /PRNewswire/ ... working to become the first U.S. commercial producer of ... signed a contract with INVAP to design ... Alachua, Fla. Mo-99 is the parent isotope ... nuclear medicine procedures worldwide. In 2012, Congress passed legislation ...
(Date:11/21/2014)... 2014   Wellcentive , the industry leader ... organizations, announced today being named one of the ... Award .  Sponsored by Intel, the world leader ... year, recognizes companies developing leading-edge technology and unique ... Wellcentive,s Mason Beard , ...
Breaking Medicine Technology:Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3
... activity reported against CTCL, PTCL and Ovarian ... -- CuraGen,Corporation , a clinical-stage biopharmaceutical company ... the clinical development,program for belinostat, a histone ... clinical activity of belinostat,against cutaneous T-cell lymphoma ...
... 12, 2007 - Critical,Therapeutics, Inc. (Nasdaq: CRTX) today ... III clinical trial of ZYFLO CR(TM),(zileuton) extended-release tablets ... Asthma. ZYFLO CR was approved by the U.S. ... Critical Therapeutics,together with its co-promotion partner Dey, L.P. ...
Cached Medicine Technology:CuraGen Presents Update on Clinical Development Program for,Belinostat 2CuraGen Presents Update on Clinical Development Program for,Belinostat 3CuraGen Presents Update on Clinical Development Program for,Belinostat 4CuraGen Presents Update on Clinical Development Program for,Belinostat 5CuraGen Presents Update on Clinical Development Program for,Belinostat 6CuraGen Presents Update on Clinical Development Program for,Belinostat 7CuraGen Presents Update on Clinical Development Program for,Belinostat 8Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5
... The STart 4 semi-automated hemostasis analyzer ... electro-mechanical clot detection (Viscosity-based Detection System). ... icteric or other optically turbid samples ... offers programmable and preprogrammed assays with ...
... The STA is a fully-automated, ... chromogenic and immunological assays in true ... method of sample management offers high ... samples without the need to interrupt ...
The CA-50 is a compact semi-automated coagulation analyzerproviding 4-parameter random access....
... The Electra 1800C is ... system that maximizes efficiency ... to the operator with ... is equipped with an ...
Medicine Products: